Melanie Doyle-Eisele, Ph.D. and Director of Life Sciences, and Philip Kuehl, Ph.D, and Director of Scientific Core Laboratories, have recently partnered with various biomedical researchers to publish the results of the recent publication entitled: Clofazimine Inhalation Suspension Demonstrates Promising Toxicokinetics in Canines for Treating Pulmonary Nontuberculous Mycobacteria Infection. Pulmonary nontuberculous mycobacteria infection, or NTM, is an opportunistic pathogen that develops continuous resistance to antibiotics. The latest publication and research on this topic investigate the usage of a novel inhaled formulation of clofazimine to resolve issues related to toxicity when taking prolonged oral antibiotics for the treatment of NTM.
Clofazimine was initially introduced as a riminophenazine antibiotic against Mycobacterium tuberculosis (MTB) and other such pulmonary diseases, however, its lipophilic and anti-inflammatory characteristics lead to mild and serious complications when administered orally. Recently, renewed interest in clofazimine has occurred as antibiotics have become less successful in treating multidrug-resistant, and extensively drug-resistant (XDR), strains of TB and NTM have emerged.
With the help of the American Society of Microbiology: Lovelace Biomedical, MarkAllen Consulting LLC, PharmBioTec Research and Development, Swabian Tech LLC, COELUS LLC, and MannKind Corporation have come together in researching and testing for the effects of clofazimine on treating pulmonary nontuberculous mycobacteria infection.